Background. The systemic effects of absorbed glucose degradation products (GDPs) contained within the conventional peritoneal dialysis solutions (cPDS) are largely unknown, while they appear to affect also cardiovascular function. The aim of the present study was to evaluate if the new bicarbonate-based less bioincompatible new peritoneal dialysis solutions ameliorate cardiac structural and functional status as well as the peritoneal net ultrafiltration (UF) and residual renal function. Patients and methods. This is a single centre, prospective cohort study of 12 stable continues ambulatory peritoneal dialysis patients (four women, eight men) mean aged 71.3 6 of 6.01 years and mean peritoneal dialysis (PD) duration 31.9 6 21.33 months, treated with the usual cPDS (Medital BieffeÒ, with increased GDPs, low pH and lactate as a buffer system). The patients changed for a 6-month period to the newer biocompatible PD solutions (BicaVera, FreseniusÒ low GDPs, normal pH, bicarbonate as a buffer) and at the end of this time, they returned to their previous schema of conventional solutions, for another 6 months. During the study period, the left ventricle ejection fraction (EF), left ventricle end systolic and diastolic diameter (LVESD, LVEDD), left ventricle mass index (LVMI), glyoxal serum and peritoneal concentrations, net UF and 24 h urine volume were repeatedly estimated: at the beginning of the study (T0), after 6 months with the biocompatible solutions (T6) and at the end of study (T12), after the 6-month period using again the cPDS. The UF volume and glyoxal concentrations were estimated at end of a 4 h dwell of an exchange with a PD solution of 2.27 % glucose.
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Results. There was a statistically significant difference between the mean levels of EF, LVESD, LVEDD, LVMI, UF and glyoxal serum and peritoneal concentrations at the beginning (T0) and in the middle of the study (T6) (for serum glyoxal P ¼ 0.005, for peritoneal glyoxal P ¼ 0.0004, for EF P ¼ 0.0004, for LVESD P ¼ 0.023, for LVEDD P ¼ 0.002, for LVMI P ¼ 0.0005 and for UF P ¼ 0.005) as well as between the mean values in the middle (T6) and at the end of the evaluation period (T12) (for serum glyoxal P ¼ 0.043, for peritoneal glyoxal P ¼ 0.006, for EF P ¼ 0.00009, for LVESD P ¼ 0.012, for LVEDD P ¼ 0.00014, for LVMI P ¼ 0.00013 and for UF P ¼ 0.048). On the other hand, no statistically significant difference was revealed between the T0 and T12 mean
Introduction
The carmelization of glucose during heat sterilization and storage of peritoneal dialysis solutions (PDS) results in the formation of glucose degradation products (GDPs) such as acetaldehyde, glyoxal, methylglyoxal and 3,4-dideoxyglucosone-3-ene [1] . GDPs are believed to be the main contributing factor in advanced glycation end product (AGE) formation [2] as well as being highly reactive substances that exert considerable toxicity on the peritoneal membrane [3] [4] [5] which are resorbed from the peritoneal cavity [6] . Muller-Krebs et al. [7] showed that the systemic application of GDP results in renal toxicity.
In order to investigate the hypothesis of systemic cardiovascular damage due to GDPs, we studied the effect of a neutral-pH (bicarbonate based) peritoneal dialysis (PD) solution (pH 7), low GDP composed of 34 mmol/L bicarbonate (Bic) prepared in a dual-chamber bag [BicaVera FreseniusÒ: new PD solution-new peritoneal dialysis solution (nPDS)], on the alteration of left ventricle ejection fraction (EF), left ventricle end systolic and diastolic diameter (LVESD, LVEDD), left ventricle mass index (LVMI) net ultrafiltration (UF) and 24-h urine volume comparing it with a conventional [Medital BieffeÒ: conventional peritoneal dialysis solution (cPDS)] acid pH solution (pH 5.5) high in GDP, containing 37.5 mEq/L lactate (Lac), with the patients acting as their own controls.
Patients and methods

Study population
The study population consisted of 12 stable PD patients (eight males, four females), aged from 60 to 77-years old, mean age 71.3 AE 6.01 years old. Their duration on PD ranged between 20 and 90 months with a mean PD duration of 31.6 AE 13 months. Diabetes was present in three patients. There was one episode of peritonitis in one of our patients during the study period (12 months). All of our PD patients fulfilled the Kidney Disease Outcomes Quality Initiative (KDOQI) targets of dialysis adequacy when they initiated the study (for baseline demographics, see Table 1 ).
Study design
This is a single centre, prospective cohort study of 12 clinical stable continues ambulatory peritoneal dialysis (CAPD) patients using cPDS before the initiation of the study for at least 6 months. At the beginning of the study, our patients started using dual-chamber bag biocompatible PDS with neutral pH, low GDPs and bicarbonate as a buffer (BicaVera FreseniusÒ) for a time period of 6 months. At the end of this time period, they returned for another 6 months to conventional (Medital BieffeÒ) PDS (acid pH, lactate as a buffer and high in GDPs).
No changes were made in any patient's oral treatment, number of peritoneal exchanges (4 2 L/day) or glucose concentration during the study.
Peritoneal equilibration test (PET) and echocardiographic measurements were performed at the initiation of the study, at the end of the period with the biocompatible solutions (after 6 months) and at the end of the study after another 6 months with cPDS. Glyoxal serum and peritoneal concentrations, the UF and dialysate and plasma for creatinine (Cr D/P) ratio were estimated at the end of a 4 h 2 L 2.27% glucose dwell of the PET at the beginning (T0), in the middle (T6) and at the end of the study (T12).
Echocardiographic examinations were performed by the same researcher at the beginning (T0) in the middle (T6) and at the end of the study (T12) using the Cardiovascular Ultrasound System Five (GE Healthcare, GE, Turnpike, CT) echocardiography device. The process was performed while the patient was lying in the decubitus position on the left side after a 5-min rest at the end of the PET test. The aim of the echocardiographic examination was to calculate left ventricle EF, LVESD, LVEDD and LVMI of the patients on the basis of the Devereux formula [8] . Accordingly, LVMI was computed, in grams, using the following formula:
]]1 0.6 g indexed to bovine serum albumin.
Glyoxal effluent and serum concentrations were measured with high pressure liquid chromatography as per the manufacturer's instructions.
During the study, we estimated monthly the urine volume, acid base balance, albumin serum levels (as an indicator of nutrition) and C-reactive protein (CRP) (as an indicator of inflammation) as well as Kt/V (peritoneal and renal) as an adequacy marker every three months.
Statistical analysis
Statistically, the results are described as means AE standard deviations. The Student's t-test for paired data was used to compare the differences of left ventricle EF, LVESD, LVEDD, LVMI net UF and 24-h urine volume at the beginning, in the middle and at the end of the study.
The project was approved by the ethics committee.
Results
The patients' average age was 71.3 AE 6.01 years (60-77 years), and the mean PD duration was 31.6 AE 13 months (20-90 months). All of our patients fulfilled the KDOQI targets of dialysis adequacy when they initiated the study. The mean value of weekly Kt/V was 2.56 AE 0.67. During the study, the patients' mean Kt/V remained above the KDOQI guidelines and with no statistically significant alterations (Table 3) . Similarly, no statistical significant alterations were observed for urine volume, glomerular filtration rate, albumin and CRP during the study period.
According to the acid-base balance during the study, there was no statistically significant alteration of serum pH or bicarbonate serum concentration.
Measures comparing data from baseline (means AE SD) of left ventricle EF, LVESD, LVEDD and LVMI revealed a significant increase of EF (P ¼ 0.0004) and a decrease in LVESD (P ¼ 0.023), LVEDD (P ¼ 0.002) and for LVMI (P ¼ 0.00052) after 6 months continuous treatment with the nPDS. The alteration of the above values in the middle of the study returned to their original levels after 6 months with the cPDS. The results revealed a statistically significant decrease of EF (P ¼ 0.000096) and an increase in LVESD (P ¼ 0.012), LVEDD (P ¼ 0.000154) and for LVMI (P ¼ 0.00013) (Figures 1-4) .
While comparing the data of left ventricle EF, LVESD, LVEDD and left ventricle mass between the beginning and the end of the study, the results did not reveal any statistically significant difference.
Comparing data (mean AE SD) from the beginning of the study (T0 0.88 AE 0.47 lmol/L) and the middle of the study (T6 0.33 AE 0.39 lmol/L), we observed a statistically significant reduction of glyoxal serum concentration (P ¼ 0.0054) after 6 months' continuous treatment with the new biocompatible bicarbonate dialysis solutions. The reduction in glyoxal serum concentration in the middle of the study returned to higher values (T12 0.58 AE 0.36 lmol/L, pT6-T12 ¼ 0.043) after 6 months with the conventional solutions (Table 2, Figure 6 ).
Also, a significant reduction (P ¼ 0.0004) was observed in effluent glyoxal levels after 6-month continuous treatment with the nPDS, (T0 1.73 AE 0.80 lmol/L to T6 0.67 AE 0.15 lmol/L), which returned to previous higher values (T12 1.21 AE 0.58 lmol/L, pT6-T12 ¼ 0.006) after 6 months with the cPDS, (Table 2, Figure 7) .
Additionally, we observed a statistically significant increase in the net UF of our patients (means of UFT0 231.66 AE 188.81 mL and of UFT6 425.83 AE 190.33 mL, P ¼ 0.005) at the end of the first 6 months when they were using new PD solutions. After they changed and remained for another 6 months with cPDS, we noticed a statistically significant decrease in all of our patients' net UF (means of UFT6 425.83 AE 190.33 mL and of UFT12 257.50 AE 159.32 mL, P ¼ 0.048). The fact that there was no GFR, glomerular filtration rate; NIDDM, non-insulin-dependent diabetes mellitus Fig. 1 . Left Ventricle EF during the study period (mean 6 SD). statistically significant difference between the beginning and the end of the study (P ¼ 0.720) may possibly suggest that the new bicarbonate-based PDS appears to play an important role in the preservation of membrane ability for UF ( Figure 5 ).
Even though there was not any statistically significant difference for creatinine D/P and mass transfer area coefficient (MTAC) during the first semester of the study period with the nPDS the ratio remaining relatively constant, it tended to increase when the patients returned for another 6 months to the cPDS resulting in statistical significant difference for D/P between T0-T12 (P ¼ 0.027) and for MTAC between T6-T12 (P ¼ 0.03) ( Table 3) .
Discussion
Analysing patient studies, it seems that the mortality risk of patients suffering from predisposed cardiovascular risk is higher for PD patients than for patients treated with haemodialysis [9, 10] . The GDPs, present in the cPDS, not only provoke local toxicity to the peritoneal membrane [11] but also systemic toxicity mediated by GDP resorption from the peritoneal cavity [12] .
Due to these observations, we might consider that the cardiovascular risk is increased for PD patients treated with GDP-containing PD solutions compared with patients treated with haemodialysis. Moreover, it was hypothesized that Fig. 2 . LVESD during the study period (mean 6 SD). Fig. 3 . LVEDD during the study period (mean 6 SD).
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M. Theodoridis et al. Fig. 4 . LVMI during the study period (mean 6 SD). Fig. 5 . UF volume at the end of a 4-h dwell 2.5% during the study.
Biocompatible PD solutions and cardiac function 4065 Fig. 6 . Glyoxal serum concentration alteration during the study (mean 6 SD). the mortality of PD patients treated with high GDP solutions is higher than for PD patients treated with low GDP solutions [13] [14] [15] . Thus, one might speculate that the cardiovascular risk could be increased as a consequence of a higher GDP load; however, these trials are not yet applicable for patient use.
In the present study, we evaluated the effect of continuous dialysis with a potentially more biocompatible, neutral pH solution buffered with bicarbonate on changes on left ventricle structure (LVESD, LVEDD, LVMI) and functional (EF) indicators in a group of CAPD stable patients.
The results of the present study indicate that continuous dialysis with less bioincompatible solutions was associated with a statistically significant improvement of functional and structural alterations of the left ventricle that were subsequently returned to their original levels at the beginning of the study when the patients reverted to acidic lactatebuffered solutions.
Finally, using the new dual-chamber bicarbonate PD solutions for 6 months led to a statistically significant reduction of glyoxal (GDPs) effluent and serum concentrations. When our patients returned and remained for another 6 months on the conventional solutions, there was a statistically significant increase for flyoxal effluent and serum concentrations. The fact that there was no statistical significant difference between the beginning and the end of the study suggests that the new biocompatible bicarbonate solutions appear to protect the peritoneal membrane from the harmful effects of GDPs and AGEs.
Additionally, we observed a statistically significant increase in the net UF of our patients at the end of the first 6 months when they were using new PD solutions. After they changed and remained for another 6 months on cPDS, we noticed a statistically significant decrease in all of our patients' net UF. The fact that there was no statistically significant difference between the beginning and the end of the study possibly suggests that the new biocompatible bicarbonate solutions appears to play an important role in the preservation of membrane ability for UF, even though there are controversial results regarding the ability of the nPDS to increase net UF.
egarding the equilibration ratio between Cr D/P, even though there was not any statistically significant alteration during the study it should be mentioned that the first 6 months creatinine D/P ration remained relatively constant in contradiction to the last 6 months when there was a tendency for higher values resulting in a statistically significant difference for creatinine D/P between T0 and T12 and for MTAC between T6 and T12. Although we cannot explain by these alterations the improvement of UF in the first 6 months, we can assume that the reduction of the UF in the second semester was due to the increase in transport through the membrane.
The use of bicarbonate-based PDS induced a statistically significant improvement of left ventricle structure (LVESD, LVEDD, LVMI) and functional (EF) indicators. These beneficial effects on the left ventricle in combination with the improvement of net UF may designate a protective role of the newer bicarbonate peritoneal solutions on cardiovascular morbidity and mortality risk of peritoneal dialysis patients.
